While reporting weak earnings and higher revenues in its third quarter, drug maker Eli Lilly And Co. (LLY) on Tuesday trimmed its fiscal 2021 earnings view on a reported basis, while raised adjusted earnings and revenue forecast above market estimates.
In pre-market activity on the NYSE, Lilly shares were gaining around 2.02 percent to trade at $250.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com